title: Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
abstract: We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB). This combination demonstrated activity against our patient's refractory HB that had been extensively treated with multiple prior chemotherapeutic regimens. The patient had stabilization of radiographic disease coupled with an 83% decrease in his alpha-fetoprotein level. Given the response in this setting and the paucity of other available options, consideration could be given to using this combination as therapy in patients with recurrent HB who have failed more traditional agents.
authors.affiliation: Department of Hematology/Oncology, Children's Hospital and Research Center Oakland, Oakland, California 94609-1809, USA.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Marsh
authors.forename: Louise
authors.initials: L
authors.lastname: Lo
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Cohen
authors.forename: James H
authors.initials: JH
authors.lastname: Feusner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage*; D000068258:Bevacizumab; D002675:Child, Preschool; D018197:Hepatoblastoma / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage*; D011859:Radiography; D000077157:Sorafenib; D000509:alpha-Fetoproteins / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D000509:alpha-Fetoproteins; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib